What ReNerve does

ReNerve is an Australian medical device company (ASX: RNV) headquartered in North Melbourne that develops tissue-based products for peripheral nerve repair and replacement, plus adjacent soft tissue surgical applications. Its core NervAlign product line comprises three devices: the FDA 510(k)-cleared Nerve Cuff (a clean, inert extracellular matrix scaffold for transected nerve repair), the Nerve Graft (an off-the-shelf nerve graft eliminating the need for autologous nerve harvest), and the Bionic Nerve (a CSIRO-co-developed ionic polymer conduit targeting 20+cm long-gap repairs). Manufacturing is built around eCOO Technology, a supercritical CO2 tissue processing method licensed from Leader Biomedical in the Netherlands, which produces extracellular matrix scaffolds free of toxic chemical residues while preserving natural crosslinking.

The company generates revenue through medical device sales of its FDA-cleared products, distributed in the United States through Emerging Surgical (San Diego) with an initial West Coast focus, and sold directly in Australia and New Zealand. End users are specialist surgeons — neurosurgeons, plastic and reconstructive surgeons, and hand surgeons — operating in hospital surgical settings. ReNerve has expanded its commercial surface with the Empliq line of lyophilized amniotic allografts and dermal matrices for wound management applications.

The business is at an early commercialization stage: with a headcount of 1–10 employees, just one FDA-cleared product in active US launch, and pipeline products still in development or clinical study, the company is scaling from a small base. Its research operations leverage partnerships with CSIRO, Monash University, Melbourne University Veterinary School, and clinical collaborators at Melbourne hospitals, and it maintains a scientific advisory board including practising microsurgeons.

Name

ReNerve

Legal name

ReNerve Ltd

Website

https://renerve.com.au

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

ReNerve is an Australian medical device company (ASX: RNV) developing tissue-based NervAlign products — FDA-cleared Nerve Cuff plus pipeline Nerve Graft and Bionic Nerve — for peripheral nerve repair, sold to specialist surgeons in the US, Australia, and New Zealand through direct and distributor channels.

Ownership category

akta.pro rank

Product category

Peripheral Nerve Repair Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

akta.pro secondary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

Keywords

• Peripheral nerve repair
• Medical device manufacturing
• Tissue scaffold products
• Amniotic allograft products
• Soft tissue regeneration

Headquarters

HQ city

North Melbourne

HQ country

Australia

HQ region

Oceania

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales - Nerve Cuff: ReNerve generates revenue through the sale of its FDA-cleared NervAlign® Nerve Cuff medical device in the United States and New Zealand markets. The company has partnered with Emerging Surgical for US distribution.
2. Medical Device Sales - Pipeline Products: Future revenue expected from NervAlign® Nerve Graft and Bionic Nerve products currently in development. These tissue-based products target peripheral nerve repair and replacement markets.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

ReNerve develops, manufactures and sells tissue-based medical devices for peripheral nerve repair and replacement, plus related soft tissue wound care products. Its NervAlign® product range (Nerve Cuff, Nerve Graft, Bionic Nerve) provides off-the-shelf surgical implants that eliminate the need for autologous nerve harvest, and the Empliq™ line offers lyophilized amniotic allografts and acellular dermal matrices for wound management. All products are produced using the proprietary eCOO® supercritical CO2 tissue processing technology.

Product overview

ReNerve is a medical device company developing tissue-based products for peripheral nerve repair and related soft tissue surgical procedures. The product portfolio includes three core NervAlign® nerve repair products: the Nerve Cuff (FDA-cleared protective wrap), the Nerve Graft (off-the-shelf replacement for longer nerve gaps), and the Bionic Nerve (combination polymer technology for extended-length repairs of 20+cm). Additionally, ReNerve offers the Empliq™ line of amniotic allograft products including Lyophilized Amniotic Allografts, Placental, Amnio-Lite, Amnio-Duo, and Dermal matrices for wound care applications. The NervAlign® products utilize proprietary eCOO® supercritical CO₂ technology for clean, non-toxic tissue processing.

Differentiator

Problem solved

Functional benefit

Brands

• NervAlign®: Product brand for nerve repair devices including Nerve Cuff, Nerve Graft, and Bionic Nerve products.
• Empliq™

Products and services

• NervAlign® Nerve Cuff A soft, compatible protective wrap used in the surgical repair of transected and damaged peripheral nerves with no gap. Manufactured using eCOO supercritical CO2 technology, producing a clean, inert extracellular matrix scaffold that protects nerves from inflammatory responses and scarring. FDA 510(k) cleared (Class II) and approved in New Zealand. Targeted at neurosurgeons, plastic/reconstructive surgeons and hand surgeons, and the hospitals that procure surgical implants.
• NervAlign® Nerve Graft Off-the-shelf nerve grafts in varying diameters and lengths for the repair of damaged peripheral nerves with long gaps. Produced from optimized animal nerve source using eCOO technology to create cleaned nerve scaffolds that enable rapid, directed nerve implant and regrowth, eliminating the need to harvest the patient's own nerve. Designed for surgeons and hospitals performing long-gap peripheral nerve repair.
• NervAlign® Bionic Nerve A novel combination polymer technology developed in conjunction with CSIRO, containing shaped ionic polymers to enable stimulation of the distal end of injured nerves. Designed to produce replacement nerves of 20+ cm that can be cut to size for large nerve damage from trauma, with potential application in spinal cord injury repair. Targeted at surgeons and hospitals performing large-gap peripheral nerve and spinal cord reconstruction.
• Empliq™ Lyophilized Amniotic Allografts Lyophilized amniotic allografts intended for homologous use as a barrier, forming a protective cover over acute and chronic wounds. Targeted at hospitals, wound care clinics and surgeons managing soft tissue wound repair.
• Empliq Placental Placental allograft including amniotic membrane and chorion, intended for wound management applications including use as a protective barrier over acute and chronic wounds.
• Empliq Amnio-Lite Single-layer amniotic membrane allograft for protective wound covering applications.
• Empliq Amnio-Duo Double-layer amniotic membrane allograft providing enhanced protective barrier properties for wound coverage applications.
• Empliq Dermal Deep-layer acellular dermal matrix (ADM) sourced from donated human skin, designed to replace lost or damaged dermal tissue.

Quantifiable outcome

• Sheep able to walk within hours post-surgery and achieve full clinical recovery within three months in animal studies
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Emerging SurgicalcoreChannel Partner/ Reseller/ Distributor · 10 February 2022ReNerve entered into an agreement with Emerging Surgical in San Diego for the launch, promotion and sales of its NervAlign Nerve Cuff in the United States. Emerging Surgical is a specialist medical device distributor with extensive track record of bringing new medical products to the US market, initially focusing on West Coast region.
• Leader BiomedicalcoreTechnology or IntegrationReNerve has licensed the proprietary supercritical CO2 technology called eCOO® Technology from Leader Biomedical in the Netherlands. The two companies have been working together over the past 3 years to develop the NervAlign Nerve Cuff product.
• Vivazome TherapeuticscoreStrategic or Co-development PartnerReNerve and Vivazome announced a collaboration to combine the NervAlign Nerve Cuff and Vivazome exosome technology for the treatment of spinal cord injury. The collaboration explores using the nerve guiding scaffold to deliver regenerative purified exosomes locally to spinal cord injury areas.
• CSIROcoreStrategic or Co-development PartnerReNerve works closely with CSIRO polymer science division at one of Australia's premier biomaterials precincts at CSIRO/Monash University. The company developed the Bionic Nerve in conjunction with CSIRO using technology and know-how published under Quigley et al, 2013 and Kaur et al, 2015.
• Monash UniversitycoreStrategic or Co-development PartnerReNerve engages with cutting edge technologies via collaborations with researchers at Monash University in the biomaterials precinct. The company also works with Melbourne University Veterinary School on nerve injury replacement animal models.
• Melbourne University Veterinary SchoolminorStrategic or Co-development PartnerReNerve developed a nerve injury replacement animal model in collaboration with Melbourne University Veterinary School to simulate human nerve injury repairs and test nerve graft generations.
• Melbourne HospitalscoreStrategic or Co-development PartnerReNerve is performing clinical studies with Melbourne hospitals in Australia. Initial readouts show presentation and protection of nerves with no negative effects.

Scale indicators4 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Integra LifeSciences: Integra LifeSciences is a diversified medical device company with a meaningful peripheral nerve repair portfolio (NeuraGen nerve guide) alongside regenerative tissue and neurosurgery products. It is a broad incumbent competitor whose nerve repair franchise overlaps directly with ReNerve's target market.
• Stryker: Stryker is a large diversified medical device company with peripheral nerve repair offerings within its broader surgical and neurosurgery portfolios. It represents an incumbent competitor with the scale and sales force that ReNerve would need to match to drive surgeon adoption.
• Organogenesis: Organogenesis is a regenerative medicine company commercialising skin and wound healing products such as Apligraf and Dermagraft. It is a comparable peer in the use of biological scaffolds for soft tissue repair, mirroring ReNerve's tissue engineering approach for nerve and wound applications.
• Smith+Nephew: Smith+Nephew is a large global medical device company with a significant advanced wound management portfolio. It represents a broad incumbent competitor for ReNerve's Empliq amniotic allograft and dermal matrix wound care products.

Direct peers

• AxoGen: AxoGen is a leading peripheral nerve repair company whose Avance nerve graft is the dominant off-the-shelf alternative for gap repairs. It is the most directly comparable commercial competitor to ReNerve's NervAlign Nerve Graft and Nerve Cuff, serving the same surgeon specialties with a similar biological implant approach.
• Cook Biotech: Cook Biotech, part of Cook Medical, develops ECM-based regenerative products including nerve repair devices using processed tissue scaffolds. It is a comparable peer in decellularised tissue technology for nerve and soft tissue repair, serving similar hospital channels.
• Polyganics: Polyganics is a Dutch medical device company developing bioresorbable nerve repair devices including the Neurolac nerve guide. It competes with ReNerve in the peripheral nerve repair space with a similar product philosophy of off-the-shelf nerve conduits and grafts for surgeons.

Others

• MTF Biologics: MTF Biologics is a tissue bank that processes and distributes allograft tissues for surgical and wound care use. It is comparable to ReNerve as a supplier of biological tissue scaffolds and could serve as an enabler or competitor in the regenerative nerve and soft tissue repair market.

Emerging players

• MiMedx: MiMedx processes and markets dehydrated amniotic membrane allografts (e.g., EpiFix, AmnioFix) for wound care and surgical applications. It is a comparable peer for ReNerve's Empliq line of lyophilised amniotic allografts, competing in the same wound barrier / soft tissue repair market.
• Collagen Matrix / Collagen Solutions: Collagen Matrix manufactures collagen- and other biomaterial-based medical devices for nerve, dura, and soft tissue repair. It is a comparable emerging peer in the use of biological matrices for peripheral nerve and soft tissue surgical applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@ReNerveLTD
• LinkedInlinkedin.com/company/renerve-ltd

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ReNerve